Replies to post #233250 on Biotech Values

[DewDiligence]

ALGS IPOs 11.5M* shares @$15.00:

https://www.globenewswire.com/news-release/2020/10/16/2109634/0/en/Aligos-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH).

ALGS is a competitor of ENTA. Please see #msg-156463352 for background info.

*Assuming exercise of underwriter’s option.